Objectives Invasive liver biopsy is the current method for the assessment of liver fibrosis. In search of noninvasive alternatives, galectin-3-binding protein (G3BP) was introduced as a candidate-marker of hepatitis C-related fibrosis based on serum proteomics. We investigated the role of G3BP as a single-marker of significant fibrosis and cirrhosis by serology and histology and studied the effect of glycosylation on antibody-affinity in hepatitis C and alcoholic cirrhosis.
Introduction
Hepatitis C viral infection is one of the major chronic liver diseases with an estimated prevalence of 3%, about 170 million cases worldwide [1, 2] . Chronic hepatitis C (CHC) patients are prone to develop liver fibrosis and cirrhosis, characterized by an excessive accumulation of extracellular matrix proteins within the liver [3, 4] . Liver fibrosis is a slow and factor-dependent (i.e. alcohol, age, sex) process and it is therefore essential to closely monitor the fibrosis-progression to initialize an appropriate antiviral treatment [3, [5] [6] [7] . Liver biopsy with subsequent histological examination is the current diagnostic standard for fibrosis assessment, but is limited because of invasiveness and potential sampling error; this has stimulated the search for noninvasive alternatives [8] [9] [10] [11] .
In this regard, we earlier analyzed the serum proteome of CHC patients in search of new protein-markers of fibrosis by means of two-dimensional gel electrophoresis and mass spectrometry; among the identified proteins, galectin-3-binding protein (G3BP) was shown to be upregulated in advanced stages of fibrosis, especially cirrhosis [12] . G3BP is a secreted 90 kDa N-glycosylated protein with affinity for galectins and extracellular matrix proteins [13] . Sudden increase in serum G3BP-levels have been reported in various infectious and cancerous diseases, including hepatitis C [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] .
An earlier study by Iacovazzi et al. [18] reported a more prominent elevation in serum G3BP-levels in viral liver cirrhosis and hepatocellular carcinoma compared with nonviral liver disease, but the exact cause of this difference remains unclear. Noteworthy, G3BP is a N-glycan-rich protein (seven binding-sites) and earlier studies have described changes in glycosylation-pattern of serum glycoproteins because of liver pathologies [13, 24, 25] . These post-translational changes could have substantial influence on antibody-affinity [26, 27] .
In this study, we investigated the role of G3BP as a single-marker of hepatitis C-related fibrosis by means of serological and histological assessment of hepatitis C patients. Furthermore, we studied the effect of glycosylation of G3BP on antibody-affinity in hepatitis C-related and alcohol-related cirrhosis.
Methods

Study population
This mono-centric study consisted of CHC patients (n = 76), alcohol-related cirrhotic patients (n = 11) (58.0 ± 8.0 years), and healthy controls (n = 5) (46.2 ± 4.2 years), registered at the Department of Gastroenterology and Hepatology at Ghent University Hospital (Ghent, Belgium) (mean ± standard deviation). All patients gave informed consent before the start of the study. The study was also approved by the Ethics Committee of the Ghent University Hospital. Viral status was confirmed by antihepatitis C virus enzyme immunoassay, hepatitis C virus RNA-PCR, whereas fibrosis-grade (F0 = no fibrosis; F1 = portal fibrosis without septa; F2 = portal fibrosis with few septa; F3 = numerous septa without cirrhosis; F4 = cirrhosis) and inflammatory activity (A0 = no activity; A1 = mild activity; A2 = moderate activity; A3 = severe activity) were assessed by liver biopsy according to the Metavir scoring-system [28, 29] . Liver specimens were at least 15 mm of length with at least six visible portal tracts; specimens were obtained by needle puncture or transjugular liver biopsy.
All patient's sera (n = 76) were stored at -201C at the Department of Gastroenterology and Hepatology, whereas available tissue specimens of CHC patients (n = 20) were obtained from the Department of Pathology at Ghent University Hospital. Patients with antiviral treatment, coinfection, severe decompensation according to the Child-Pugh score (> score A) (bilirubin > 2 mg/dl, albumin < 3.5 mg/dl, international normalized ratio > 1.7, ascites and encephalopathy) or hepatocellular carcinoma were excluded from the study.
Serum G3BP measurement
Serum G3BP-levels were measured by means of a commercially available enzyme-linked immunosorbent assay (ELISA) (BMS234, Bender MedSystems, Vienna, Austria). In brief, patient's sera were diluted and loaded onto a monoclonal antibody-coated 96-microwell plate. The plate was incubated at 371C for 45 min, subsequently washed and reincubated with a second monoclonal horseradish peroxidase (HRP)-labeled antibody at 371C for 45 min. After repeating the washing procedure, tetramethylbenzidine substrate solution was added to the wells and incubated at room temperature for 15 min while shaking at 100 rpm. Substrate reaction was stopped after addition of an acid-based stop solution. Absorbance was measured and analyzed by ultraviolet-visible spectrophotometry (Safire 2 , Tecan, Männedorf, Switzerland) at 450 nm; serum G3BP-levels were determined by plotting the standard curve. The intra-assay and interassay coefficients of variation were 5.5 and 11.9%, respectively, according to user's manual.
G3BP immunohistochemistry
Paraffin-embedded sections (5 mm) were dewaxed in an isoparaffin-based clearing agent (UltraClear, Klinipath, Geel, Belgium) and rehydrated in graded ethanol baths (99 and 96%) (Klinipath). Antigen retrieval was performed with citrate buffer, containing 10 mmol/l sodium citrate (pH 6) (Sigma-Aldrich, Steinheim, Germany) and 0.05% Tween-20 (MP Biomedicals, Solon, Ohio, USA) at 951C for 20 min. Nonspecific sites on the slides were blocked with phosphate buffer saline (PBS) (pH 7.4) (Invitrogen, Grand Island, New York, USA) containing 1% (w/v) bovine serum albumin (Sigma-Aldrich) and 0.3% (v/v) Triton-X (Sigma-Aldrich) for 10 min. Subsequently, tissue sections were incubated with primary G3BP antibody (1 : 200) (R&D Systems, Oxfordshire, UK) overnight at 41C. Endogenous peroxidase-activity was blocked with PBS (pH 7.4) (Invitrogen) containing 3% (v/v) H 2 O 2 and 1% (w/v) sodiumazide (NaN 3 ) (Sigma-Aldrich) at room temperature for 20 min. After subsequent incubation in biotinylated secondary antibody and streptavidin-HRP (LSAB + system-HRP, Dako, Carpinteria, California, USA), G3BP-expression was visualized by diaminobenzidine (DAB Substrate-Chromogen System, Dako) and haematoxylin-mayer (J.T. Baker, Deventer, Holland). Sections were eventually dehydrated in 96 and 99% ethanol (Klinipath) and isoparaffin-based solution (Klinipath). Primary antibody was replaced by normal goat immunoglobulin G (1 : 100) (Santa Cruz Biotechnology, Santa Cruz, California, USA) as negative control.
Staining intensity of G3BP was blindly assessed by a single pathologist (L.L.) without earlier knowledge of the patient's condition at the moment of scoring. Protein stain in the liver parenchyma was either absent (0), centrolobular (1) or panlobular (2) [15] .
Deglycosylation of serum G3BP
Denatured serum proteins (1 mg/ml) were prepared by sample dilution in 20 mmol/l ammoniumbicarbonate (pH 8.0) (Sigma-Aldrich) and subsequent denaturation in 0.2% sodium dodecyl sulphate (SDS) (MP Biomedicals) and 100 mmol/l b-mercaptoethanol (Sigma-Aldrich) at 1001C for 10 min. One microliter peptide: N-glycosidase F (0.5 IUB mU PNGaseF) (Sigma-Aldrich) was added to the samples and incubated at 371C for 3 h. The enzymatic reaction was stopped by heating up to 951C for 5 min in nonreducing sample buffer (Thermo Scientific, Rockford, Illinois, USA) with 5% b-mercaptoethanol (Sigma-Aldrich). Simultaneously, raw serum proteins (15 mg) were denatured in Laemmli-buffer at 951C for 5 min. Laemmli-buffer contained 50 mmol/l TrisHCl (pH 6.8) (MP Biomedicals), 2% (w/v) SDS (MP Biomedicals), 3 mol/l urea (Sigma-Aldrich), 10% (v/v) glycerol (MP Biomedicals) and 5% (v/v) b-mercaptoethanol (Sigma-Aldrich). Samples were resolved on a 10% SDS-polyacrylamide gel in an electrophoresis cell (Criterion Cell, Bio-Rad, Hercules, California, USA) at 150 and 200 V for 30 min and 1 h 30 min, respectively. The resolving gel contained 40% acrylamide : bisacrylamide (29 : 1) (Bio-Rad), 1. Protein transfer and loading were checked using 0.1% (w/v) Ponceau-S (Sigma-Aldrich) in 5% (v/v) acetic acid (Merck, Hohenbrunn, Germany). Then, the blot was blocked with PBS (pH 7.4) (Invitrogen) containing 1% (w/v) bovine serum albumin (Sigma-Aldrich) and 0.1% (v/v) Tween-20 (MP Biomedicals) for 1 h. Subsequently, the blot was incubated with primary G3BP antibody (1 : 400) (R&D Systems) overnight at 41C. The blot was washed and incubated with a secondary HRP-labelled bovine anti-goat antibody (1 : 10 000) (Santa Cruz Biotechnology) for 1 h. After repeating the wash steps, primary antibody was detected by chemiluminiscence using luminol/H 2 O 2 (SuperSignal West Dura, Thermo Scientific) and imaging System (Versadoc, Bio-Rad). Protein band patterns were analyzed using appropriate software (Quantity One, Bio-Rad).
Statistical analysis
Fibrosis-grades according to the Metavir scoring-system were regrouped into three consecutive stages: mild fibrosis (F0-F1), moderate fibrosis (F2-F3), and cirrhosis (F4). Inflammatory activity grades were regrouped into two stages: mild activity (A0-A1) and significant activity (A2-A3). Genotypes were regrouped into genotype 1-4, 2-3, and others according to earlier findings, suggesting a more prominent increase of serum G3BP-levels in genotype 1 and 4 [14, 15, 17, 20] .
Continuous data and categorical/nominal data were analyzed in accordance with fibrosis-grades by means of analysis of variances and Fisher's exact test, respectively. Data was log-transformed if appropriate.
Receiver operator characteristic (ROC) curves and area under the curve (± standard error; 95% confidence interval) were calculated to evaluate the performance of serum G3BP as a single-marker in the detection of significant fibrosis (F2-F4), severe fibrosis (F3-F4), and cirrhosis (F4). Statistical analyses were performed in SPSS v. 15 .0 (SPSS, Chicago, Illinois, USA) and R v.2.9.1 (R-software). A P value of less than 0.05 was considered statistically significant.
Results
Serum G3BP
Serum G3BP-levels, measured by ELISA, were associated with hepatitis C-related fibrosis-grades (P < 0.001), as were age at sampling and albumin amount (Table 1) . Moreover, post-hoc analysis showed an increase during cirrhosis (F4) (22.7 ± 10.1 mg/ml) compared with precirrhotic stages (F0-F1; F2-F3) (P < 0.001 and P = 0.004, respectively) (mean ± standard deviation). Despite significant distinction between fibrosis-grades, albumin, bilirubin, and international normalized ratio-values did not drastically exceed normal reference-values (Table 1) . of significant fibrosis (F2-F4), severe fibrosis (F3-F4) and cirrhosis (F4), respectively (Fig. 1a ). On the basis of these ROC-curves, G3BP had 60% sensitivity and 65% specificity for the detection of F2-F4, when levels were above 12.9 mg/ml. When levels were above 13.5 mg/ml, G3BP had 68% sensitivity and 69% specificity for the detection of F3-F4, while levels above 16.9 mg/ml had 70% sensitivity and 75% specificity for the detection of F4 (Fig. 1b) .
ROC-curves
Hepatic G3BP
Immunohistochemistry of hepatitis C-related specimens showed positive, granular G3BP staining within cytoplasm of hepatocytes and occasional staining of reactive bile ductules and bile canaliculi (Fig. 2) .
Statistical outcomes of the biopsy-population were similar to the total hepatitis C population of this monocentric study ( Table 2) . Positive hepatocellular expression was shown to be correlated with fibrosis-grades and steatosis (P = 0.002 and 0.007, respectively) and was independent of patient's sex, viral genotype, and inflammatory activity. Analysis of the histological expression in association with fibrosis grade resulted in the following characteristics:
F0-F1 was characterized by weak and moderate, centrolobular expression, F2-F3 was characterized by moderate, centrilobular and diffuse, panlobular expression, whereas F4 was only associated with diffuse, panlobular expression ( Fig. 2a, b and c, respectively). The difference in histological expression was significant between F0-F1 and F4 following post-hoc analysis (P < 0.05).
Moreover, serum G3BP levels and immunohistochemistry were significantly associated with each other (P = 0.038). Diffuse, panlobular expression was associated with a mean G3BP concentration of 25.1 ± 9.9 mg/ml.
Hepatitis C-related versus alcohol-related cirrhosis
In general, cirrhosis is more or less the same in all the chronic liver diseases being characterized by an overall loss of normal liver structure and formation of regenerative nodules [30] . In addition, histological G3BPexpression in alcoholic liver specimen showed a similar diffuse staining pattern ( Fig. 2d ).
At serum G3BP-level, both hepatitis C-related (22.7 ± 10.1 mg/ml) and alcohol-related cirrhosis (13.5 ± 9.0 mg/ml) showed a significant increase in contrast to healthy controls (3.2 ± 1.3 mg/ml) (P < 0.001) as stated earlier [18] . Moreover, serum levels in hepatitis C-related cirrhosis were more elevated than in alcoholic cirrhosis (P = 0.009) (Fig. 3a) . Alcoholic patients did not show severe decompensation at the time of sampling (data not shown).
The effect of glycosylation on the antibody-affinity for G3BP was studied by means of deglycosylation and western blot. Earlier outcomes obtained by western blot were closely correlated with the G3BP-ELISA (P < 0.001) (Fig. 3b ). Normal protein band was detected at ± 100 kDa, while deglycosylation resulted in two minor bands at 60 ± kDa (Fig. 3c) [31] . The presence of two bands might be the result of incomplete deglycosylation or other possible modifications. Despite these results, no difference could be detected in normal and deglycosylated G3BP-bands and patterns between both etiologies. 
Discussion
Noninvasive assessment of liver fibrosis in CHC patients has evolved rapidly in the past 10 years because of new pathological insights and technologies. Diagnostic techniques, such as the Fibroscan, have already been implemented into daily practice [32, 33] . New technologies such as proteomics and glycomics enable new ways to discover useful disease markers [12, 24, 34, 35] . Our earlier serum proteome study in hepatitis C patients identified G3BP as a marker of advanced fibrosis, especially cirrhosis [12] .
In this study, we investigated the role of G3BP as a single-marker of significant hepatitis C-related fibrosis and cirrhosis by means of serological and histological testing. Serum measurement and subsequent univariate analysis confirmed our earlier proteome findings, showing an increase in protein level towards end-stage liver disease. Like most single-marker studies, clear distinction was observed between the two most extreme stages (F0-F1 and F4) with substantial overlap between the other stages. Although serum G3BP had a low accuracy for the detection of significant fibrosis compared to other known noninvasive markers (i.e. glycoprotein laminin), diagnostic accuracy steadily improved for the detection of advanced fibrosis and cirrhosis [36, 37] . However, performance can be improved by combining these noninvasive markers in an appropriate diagnostic model [36, 38] . In this regard, G3BP might be a good candidate-marker for the detection of hepatitis C-related cirrhosis marker.
In contrast to many earlier marker reports, we confirmed our proteome findings by immunohistochemistry of hepatitis C-related liver biopsies with varying fibrosis grades. The histological population was overall representative for the overall hepatitis C population based on the patient's characteristics. Moreover, despite the limited sample size, we were able to confirm a similar increase in G3BP at hepatic tissue level. A clear distinction in hepatocellular expression was observed between mild fibrosis (F0-F1) and cirrhosis (F4), which was characterized by a clear zonular expression in centrolobular and panlobular areas; the latter one was associated with a clear increase in serum G3BP-levels. Hepatic G3BP-expression was also accompanied by hepatic steatosis, a common feature of chronic hepatitis C; earlier reports have associated steatosis with fibrosis progression and severity [39] [40] [41] [42] [43] [44] .
Besides hepatocellular expression, occasional G3BPstaining was detected in reactive bile ductules and canaculi, which has not been reported earlier. Bile ductular reaction is known to increase during hepatitis C-related cirrhosis development because of bile ductular metaplasia [45, 46] . This might imply a potential role for G3BP in very early stages of neoplasia or abnormal cellular manifestations, which has been observed in the bile proteome and biliary tract carcinoma [21, 47] . On the other hand, detection in canaliculi might indicate an active protein secretion by hepatocytes into the extracellular space.
In addition, a significant difference in serum G3BP-levels was detected between hepatitis C-related and alcoholrelated cirrhosis, confirming earlier findings [18] . We investigated whether antibody-affinity could be affected 
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Serum galectin-3-binding protein (G3BP) levels in healthy controls, hepatitis C-related and alcohol-related cirrhosis and the effect of glycosylation on antibody affinity by means of enzyme-linked immunosorbent assay (ELISA) (a) and western blot (b and c), respectively. G3BP-levels are significantly different between cirrhotic patients and healthy controls according to analysis of variances after log-transformation (**P < 0.001); moreover, G3BP-levels are higher in hepatitis C than alcoholic disease (*P = 0.009) (a). Western blot shows correlation with ELISA-outcome and normal G3BP protein-bands are detected at ± 100 kDa (b). Deglycosylation of G3BP results in a mass-shift from ± 100 kDa (3 and 5) to ± 60 kDa (4 and 6) (c).
Deglycosylated G3BP (arrows) shows no significant difference in pattern between alcohol-related and hepatitis C-related cirrhosis. G3BP in the healthy control (lane 1 and 2) are below detection limit. Error bar graph represents mean values with bars representing standard error of the mean.
Galectin-3-binding protein in liver fibrosis Cheung et al. 1071 by changes in glycosylation pattern of G3BP in both etiologies, because N-glycans have an intrinsic effect on antibody binding [26, 27] . In this regard, we studied the effect of glycosylation on antibody affinity by means of N-glycan removal and Western blot. Earlier findings by Western blot using a polyclonal antibody (same as immunohistochemistry) were well correlated with our ELISA-outcome, allowing us to study this effect. However, protein detection was not likely to be affected by glycosylation according to our recent findings, illustrating a more in-vivo alteration in gene or protein regulation because of etiological differences [3, 4, [48] [49] [50] [51] [52] . Evidence of such alterations in hepatitis C has been provided by Bigger et al. [53] reporting a change in hepatic gene regulation during the course and clearance of viral hepatitis C in primates. In addition, earlier studies have associated increased serum G3BP-levels with viral genotype 1-4 [14, 15, 17, 20] . Despite the increase in both cirrhosis-types, G3BP upregulation was more associated with liver fibrosis in viral liver disease than alcoholic liver disease according to these findings.
G3BP is believed to have immuno-modulating and cytokine-modulating properties, but the actual functional role in viral hepatitis C and liver fibrosis remains unclear [54, 55] . On the other hand, binding-partner galectin-3 has been widely associated with active regulation of fibrosis [56, 57] . The absence of G3BP-stain at the actual fibrotic lesions and lack of correlation with inflammation in our study are both suggestive of a possible indirect involvement in hepatitis C-related liver fibrosis [31] . In addition, the increase in protein levels in sera and tissue at cirrhotic stage could also be an indication of early neoplastic events [18, 21] .
In conclusion, we provided confirmation of our proteome study and substantial evidence that G3BP-expression is representative for the progressive, aggravating events of the liver after viral hepatitis C at a serological and histological level. At a single-marker level serum G3BP shows potential as an indicator of compensated cirrhosis, especially in viral hepatitis C. It might therefore be interesting to integrate this serum protein in multimarker tests for the detection of hepatitis C-related liver fibrosis [58, 59] .
